Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for NSCLC.

Primary tabs

field_vote: 
Average: 7 (1 vote)
Publication type: 
Number of included patients: 
References: 
Therapeutic Substance(s): 

Systemic chemotherapy using paclitaxel
and carboplatin plus regional hyperthermia and hyperbaric oxygen
treatment for non-small cell lung cancer with multiple pulmonary
metastases: Preliminary results.
Authors:
Ohguri, Takayuki1

Imada, Hajime1Narisada, Hiroyuki2Yahara, Katsuya1Morioka, Tomoaki1Nakano, Keita1Miyaguni, Yasuhiro1Korogi, Yukunori1
Source:
International Journal of Hyperthermia; Mar2009, Vol. 25 Issue 2, p160-167, 8p, 1 chart, 1 graph
Abstract:
Purpose:
The purpose of this retrospective case series was to evaluate the
toxicity and efficacy of systemic chemotherapy using paclitaxel and
carboplatin plus regional hyperthermia (HT) and hyperbaric oxygen
treatment (HBO) for non-small-cell lung cancer (NSCLC).
Materials and
methods:
Twenty-two patients with NSCLC with multiple pulmonary
metastases intravenously received paclitaxel (50 mg/m2), carboplatin
(area under the curve of 1.0-1.5) and 10% glucose weekly for 3 out of 4
weeks. Hyperthermia (HT) of the whole thoracic region was also
administered weekly during intravenous infusion of carboplatin in all
patients. In addition, 16 (72%) of 22 patients received hyperbaric
oxygen (HBO) treatment immediately after weekly chemotherapy. A total
of 107 cycles were performed in 16 patients with HBO, and 27 cycles in
6 patients without HBO. The toxicity and efficacy of these patients
were retrospectively analyzed.
Results: Both the hematologic and
non-hematologic toxicities were mild and leucopenia/neutropenia of ?
grade 3 was seen in one patient, while pneumonitis of ? grade 3
occurred in one patient. Fourteen (64%) of 22 patients had an objective
response. The median time to progression of disease in all patients was
8 months and in 16 patients with HBO was 9 months. Four (44%) of 9
patients with prior chemotherapy including paclitaxel and carboplatin
obtained objective responses.
Conclusions: The novel combined therapy
of paclitaxel and carboplatin with HT and HBO may therefore be a
feasible and promising modality for treating NSCLC with multiple
pulmonary metastases, and the results justify further evaluation to
clarify the benefits of this treatment regimen.